Three experts for super-resolution microscopy jointly want to obtain better images of functioning and pathologically altered nerve cells. The European Research Council ERC is funding them with eleven million euros.

• The combination therapy is a new treatment option for CF patients who are homozygous for F508del
• The only medicine to treat the underlying cause of CF in this age group with one F508del mutation and one of 14 residual function mutations

CHICAGO — BASE10 Genetics and DNA Link today announced their collaboration on a research project to evaluate the usability of DNA Link’s AccuFind COVID-19 IgG antibody test in a healthcare setting.

• Global biotechnology leader in animal genetics reports continued strong performance for the period from July 1, 2020 through November 24, 2020
• Company reports growth in volumes, revenues and operating profits in both porcine and bovine genetics operations
• Annual General Meeting to be held today at 11:00 AM GMT

LUND — Cantargia AB (OMXS: CANTA) and BioInvent International AB (OMXS: BINV), today announced that BioInvent has been contracted as manufacturer of Cantargia’s antibody CAN10 in preclinical development for the treatment of systemic sclerosis and myocarditis.

LONDON — Haoma Medica announced today the completion of a first-in-human trial for NaQuinate, a naphthoquinone carboxylic acid, which is being developed as a novel orally administered therapeutic for osteoporosis.

Egle to receive R&D milestone payment and equity funding from Takeda

DURHAM, N.C. — Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS® genome editing platform, today announced that its Chief Scientific Officer, Derek Jantz, Ph.D., will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference, November 30 – December 3, 2020.

NEW YORK — MindMed (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ), a leading psychedelic medicine biotech company, is establishing a digital medicine division known as Albert. Albert is in the process of assembling and recruiting a leading team of technologists, therapists, and clinical drug development experts to help the company research, develop and build an integrated technical platform and comprehensive toolset aimed at delivering psychedelic inspired medicines and experiential therapies combined with digital therapeutics.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy for you.